Hansa Biopharma deploys Cradle’s AI platform to design novel immunomodulatory therapies targeting autoimmune diseases. The collaboration focuses on developing treatments for rare IgG-related immunologic conditions. Hansa Biopharma leverages Cradle’s end-to-end protein design and engineering capabilities to accelerate drug discovery.
Cradle CEO Stef van Grieken discusses how AI agents can speed up drug discovery and lab workflows in life sciences. She highlights their limitations, particularly in handling real-world experimental feedback from wet-lab processes. Van Grieken emphasizes the continued necessity of hands-on lab validation alongside AI-driven tools.
Lundbeck scientists are using Cradle’s AI-powered software to design antibodies for two drug development programs. The collaboration leverages Cradle’s platform to accelerate antibody discovery in pharmaceutical research. No specific details about the programs or outcomes are disclosed.
Bayer partners with Cradle to integrate its AI-driven protein engineering platform into R&D workflows. The collaboration aims to accelerate lead generation and optimization for Bayer’s therapeutic antibody pipeline over three years. Cradle’s generative AI software will support antibody discovery and refinement efforts.
